Live price temporarily unavailable.
Bluejay Diagnostics (BJDX) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | $249.0K | — | — | — |
| Gross profit | — | — | $48.9K | — | — | — |
| Gross margin | — | — | 19.6% | — | — | — |
| Operating income | −$1.20M | −$3.23M | −$9.32M | −$10.3M | −$7.17M | −$6.95M |
| Operating margin | — | — | −3741.5% | — | — | — |
| Net income | −$1.16M | −$3.49M | −$9.30M | −$9.95M | −$7.72M | −$6.85M |
| Net margin | — | — | −3733.1% | — | — | — |
| EPS (diluted) | −$37888000000.00 | −$131200.00 | −$14752.00 | −$726296.00 | −$456.75 | −$15.25 |
| Balance sheet | ||||||
| Cash and equivalents | $912.4K | $19.0M | $10.1M | $2.21M | $4.30M | $5.16M |
| Total assets | $1.52M | $21.0M | $13.5M | $4.87M | $6.66M | $7.12M |
| Total liabilities | $1.85M | $637.2K | $1.98M | $1.97M | $927.9K | $1.14M |
| Shareholders' equity | −$4.21M | $20.4M | $11.5M | $2.89M | $5.73M | $5.98M |
| Cash flow | ||||||
| Operating cash flow | −$508.7K | −$4.37M | −$7.74M | −$8.31M | −$7.82M | −$6.05M |
| Capital expenditure | — | $23.9K | $1.20M | $704.2K | $306.8K | $173.7K |
| Free cash flow | — | −$4.39M | −$8.94M | −$9.02M | −$8.13M | −$6.23M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$1.36M | −$1.48M | −$1.89M | −$1.99M | −$1.62M | −$1.46M | −$1.94M | −$2.35M |
| Net income | −$1.48M | −$1.43M | −$1.86M | −$1.96M | −$1.60M | −$1.43M | −$1.92M | −$2.32M |
| EPS (diluted) | −$307.76 | $79827.65 | −$13.46 | −$5.64 | −$4.04 | $7.89 | −$1.95 | −$1.12 |
| Balance sheet | ||||||||
| Cash and equivalents | $5.76M | $4.30M | $3.12M | $4.44M | $3.08M | $5.16M | $3.68M | $9.60M |
| Total assets | $8.35M | $6.66M | $5.28M | $6.40M | $4.89M | $7.12M | $5.60M | $11.5M |
| Total liabilities | $1.19M | $927.9K | $1.41M | $1.11M | $1.20M | $1.14M | $1.42M | $2.12M |
| Shareholders' equity | $7.16M | $5.73M | $3.87M | $5.29M | $3.69M | $5.98M | $4.18M | $9.41M |
| Cash flow | ||||||||
| Operating cash flow | −$2.15M | −$1.45M | −$1.18M | −$2.05M | −$1.36M | −$1.45M | −$1.59M | −$1.50M |
| Capital expenditure | $227 | $1.13K | — | — | — | — | $19.0K | $142.8K |
| Free cash flow | −$2.15M | −$1.45M | — | — | — | — | −$1.61M | −$1.64M |
From Bluejay Diagnostics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Bluejay Diagnostics in our feed yet.